Zhang B. et al. noted that immunotherapy utilizing PD-1 or PD-L1 inhibitors has received approval for various advanced human cancers, such as SCC of the lung, esophagus, skin, and head and neck [32]. This evidence concerns the gene CD274 and cancer.